Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial

Inclusion Criteria:

• Subject is an acceptable candidate for treatment with a drug-eluting stent inaccordance with the applicable guidelines on percutaneous coronary interventions andthe Instructions for Use of the ABSORB BVS strategy and XIENCE family.

• Subject is able to verbally confirm understanding of risks, benefits and treatmentalternatives of receiving the ABSORB BVS strategy and he/she or his/her legallyauthorized representative provides written informed consent prior to any ClinicalInvestigation related procedure, as approved by the appropriate Ethics Committee.

Exclusion Criteria:

• Subject is younger than 18 years of age

• Subject has a true bifurcation lesion where a priori two scaffold/stent strategy isplanned.

• Unsuccessful predilation of one or more of the planned lesion to be treated.

• Planned treatment of in-stent restenosis of a previously placed metallic stent.

• Subject has one or more lesion planned to be treated with a scaffold/stent diametersize smaller than 2.5 mm or greater than 4.0 mm.

• Subject has one or more lesion planned to be treated with a stent/scaffold lengthgreater than 70 mm and/or overlapping of four or more scaffolds/stents.

• Subject has known hypersensitivity or contraindication to aspirin, both heparin andbivalirudin, antiplatelet medication specified for use in the study (clopidogrel,prasugrel and ticagrelor, inclusive), everolimus, poly (L-lactide), poly (DL-lactide),cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrastsensitivity that cannot be adequately pre-medicated.

• Subjects pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. (Female subjects of child-bearing potential musthave a negative pregnancy test done within 28 days prior to the index procedure andcontraception must be used during participation in this trial)

• Subjects with a limited life expectancy less than one year.

• Subjects with factors that impede clinical follow-up (e.g. no fixed abode).

• Subject is already participating in another clinical investigation that has not yetreached its primary endpoint.

• Subject is belonging to a vulnerable population (per investigator's judgment, e.g.,subordinate hospital staff or sponsor staff) or subject unable to read or write.